Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse

被引：2
|
作者：
Thomas, Xavier
Rijneveld, Anita W.
Fracchiolla, Nicola
Salek, Cyril
Spyridonidis, Alexandros
Chiaretti, Sabina
Alam, Naufil
Grueter, Isabella Pezzani
Mohammad, Abeera
Kormany, William
Kreuzbauer, Georg
Rambaldi, Alessandro
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134470
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States
    Zhang, Xinke
    Song, Xue
    Lopez-Gonzalez, Lorena
    Jariwala-Parikh, Krutika
    Cong, Ze
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (05) : 573 - 580
  • [32] Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
    Short, Nicholas J.
    Kantarjian, Hagop
    Ravandi, Farhad
    Huang, Xuelin
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Kadia, Tapan M.
    Jain, Nitin
    Alvarado, Yesid
    Yilmaz, Musa
    Khoury, Joseph D.
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Kornblau, Steven M.
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Garris, Rebecca
    Schroeder, Heather M.
    Milton, Anna
    Rivera, Juan
    Banks, Glenda
    Jabbour, Elias J.
    BLOOD, 2021, 138
  • [33] BLINATUMOMAB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA (BCP-ALL): A PHASE I/II STUDY
    Locatelli, F.
    Gore, L.
    Zugmaier, G.
    Handgretinger, R.
    Rizzari, C.
    Trippett, T. M.
    Borkhardt, A.
    Rheingold, S. R.
    Bader, P.
    Bhojwani, D.
    Cooper, T. M.
    DuBois, S. G.
    O'Brien, M. M.
    Zwaan, C. M.
    Holland, C.
    Mergen, N.
    Fischer, A.
    Zhu, M.
    Hijazi, Y.
    Whitlock, J.
    von Stackelberg, A.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S361 - S362
  • [34] Disease Burden Subgroup Analysis of HealthRelated Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study ( TOWER)
    Stein, Anthony S.
    Zimmerman, Zachary F.
    Cannell, Paul
    Dombret, Herve
    Maertens, Johan
    Topp, Max S.
    Franklin, Janet L.
    Cong, Ze
    Zhang, Xinke
    Li, Yan
    Schuh, Andre
    BLOOD, 2018, 132
  • [35] Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
    Haddad, Fadi
    Kantarjian, Hagop
    Short, Nicholas J.
    Sasaki, Koji
    Ravandi, Farhad
    Kebriaei, Partow
    Huang, Xuelin
    Jain, Nitin
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Champlin, Richard E.
    Kadia, Tapan M.
    Takahashi, Koichi
    Daver, Naval
    Khoury, Joseph D.
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Jacob, Jovitta
    Garris, Rebecca
    O'Brien, Susan M.
    Jabbour, Elias J.
    BLOOD, 2021, 138
  • [36] SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
    Advani, Anjali S.
    Moseley, Anna
    O'Dwyer, Kristen M.
    Wood, Brent L.
    Fang, Min
    Wieduwilt, Matthew J.
    Aldoss, Ibrahim
    Park, Jae H.
    Klisovic, Rebecca B.
    Baer, Maria R.
    Stock, Wendy
    Bhave, Rupali R.
    Othus, Megan
    Harvey, Richard C.
    Willman, Cheryl L.
    Litzow, Mark R.
    Stone, Richard M.
    Sharon, Elad
    Erba, Harry P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (14) : 1574 - +
  • [37] Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France
    Megane Caillon
    Benoit Brethon
    Chrissy van Beurden-Tan
    Romain Supiot
    Antoine Le Mezo
    Jean-Vannak Chauny
    Istvan Majer
    Arnaud Petit
    PharmacoEconomics - Open, 2023, 7 : 639 - 653
  • [38] Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France
    Caillon, Megane
    Brethon, Benoit
    van Beurden-Tan, Chrissy
    Supiot, Romain
    Le Mezo, Antoine
    Chauny, Jean-Vannak
    Majer, Istvan
    Petit, Arnaud
    PHARMACOECONOMICS-OPEN, 2023, 7 (4) : 639 - 653
  • [39] Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)
    Topp, Max S.
    Zimmerman, Zachary F.
    Cannell, Paul
    Dombret, Herve
    Maertens, Johan
    Stein, Anthony S.
    Franklin, Janet L.
    Cong, Ze
    Zhang, Xinke
    Schuh, Andre
    BLOOD, 2018, 132
  • [40] Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns
    Barsan, Valentin
    Li, Yimei
    Prabhu, Snehit
    Baggott, Christina
    Nguyen, Khanh
    Pacenta, Holly
    Phillips, Christine L.
    Rossoff, Jenna
    Stefanski, Heather
    Talano, Julie-An
    Moskop, Amy
    Baumeister, Susanne
    Verneris, Michael R.
    Myers, Gary Douglas
    Karras, Nicole A.
    Cooper, Stacy
    Qayed, Muna
    Hermiston, Michelle
    Satwani, Prakash
    Krupski, Christa
    Keating, Amy
    Fabrizio, Vanessa
    Chinnabhandar, Vasant
    Kunicki, Michael
    Curran, Kevin J.
    Mackall, Crystal L.
    Laetsch, Theodore W.
    Schultz, Liora M.
    ECLINICALMEDICINE, 2023, 65
12345